Nicola Wealth Management LTD. Sells 16,000 Shares of IDEXX Laboratories, Inc. $IDXX

Nicola Wealth Management LTD. trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 46.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,800 shares of the company’s stock after selling 16,000 shares during the quarter. Nicola Wealth Management LTD.’s holdings in IDEXX Laboratories were worth $12,011,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in IDEXX Laboratories by 156.2% during the second quarter. Bank of New York Mellon Corp now owns 1,451,390 shares of the company’s stock valued at $778,439,000 after buying an additional 884,808 shares during the last quarter. Generation Investment Management LLP bought a new position in shares of IDEXX Laboratories in the second quarter worth about $304,277,000. Norges Bank bought a new stake in IDEXX Laboratories during the 2nd quarter worth approximately $221,955,000. Schroder Investment Management Group lifted its holdings in IDEXX Laboratories by 295.1% during the second quarter. Schroder Investment Management Group now owns 315,785 shares of the company’s stock valued at $169,368,000 after purchasing an additional 235,863 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. boosted its position in shares of IDEXX Laboratories by 50.3% in the second quarter. Montrusco Bolton Investments Inc. now owns 429,409 shares of the company’s stock worth $224,153,000 after purchasing an additional 143,641 shares during the period. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. boosted their target price on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. BTIG Research lifted their price objective on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings raised IDEXX Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, January 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, November 4th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $763.50.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by insiders.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $697.82 on Tuesday. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The company has a market capitalization of $55.72 billion, a PE ratio of 55.34, a P/E/G ratio of 3.71 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. The company has a 50-day simple moving average of $706.41 and a two-hundred day simple moving average of $657.44.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. IDEXX Laboratories’s revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.